Rudolf-Becker-Laboratory
(financed by the Rudolf Becker Foundation)
at the Biomedical Center (BMZ) University of Bonn Medical Center

 

Publications

Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions.

Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait J, GudaC, Ran S, Hollingsworth MA, Singh RK, Talmadge JE, *Muders MH, Batra SK, *Datta K.
Cancer Res. 2018; 78(19): 5600-5617.
*corresponding author

 

Role of neuropilin-2 in the immune system.

Schellenburg S, Schulz A, Poitz DM, Muders MH.
Mol Immunol. 2017; 90: 239-244.

 

Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.

Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH.
Int J Cancer 2015; 136(2): 443-51.

 

Autophagy: detection, regulation and its role in cancer and therapy response.

Hönscheid P, Datta K, Muders MH.
Int J Radiat Biol. 2014;90(8):628-35.

 

Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance.

Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Hönscheid P, Sinicrope FA, Tindall DJ, *Muders MH, *Datta K.
Cancer Res. 2013;73(1):160-71.
*corresponding author

 

Lymphangiogenesis in regional lymph nodes is an independent prognostic marker in rectal cancer patients after neoadjuvant treatment.

Jakob C, Aust DE, Liebscher B, Baretton GB, Datta K, Muders MH.
PLoS One. 2011;6(11):e27402.

 

Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.

Muders MH, Zhang H, Wang E, Tindall DJ, Datta K.
Cancer Res. 2009;69(15):6042-8.

 

Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth.

Muders MH, Vohra PK, Dutta SK, Wang E, Ikeda Y, Wang L, Udugamasooriya DG, Memic A, Rupasinghe CN, Baretton GB, Aust DE, Langer S, Datta K, Simons M, Spaller MR, Mukhopadhyay D.
Clin Cancer Res. 2009;15(12):4095-103.

 

Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma.

Muders MH, Dutta SK, Wang L, Lau JS, Bhattacharya R, Smyrk TC, Chari ST, Datta K, Mukhopadhyay D.
Cancer Res. 2006;66(21):10264-8.

 

Epigenomic map of human liver reveals principles of zonated morphogenic and metabolic control.

Brosch M, Kattler K, Herrmann A, von Schönfels W, Nordström K, Seehofer D, Damm G, Becker T, Zeissig S, Nehring S, Reichel F, Moser V, Thangapandi RV, Stickel F, Baretton G, Röcken C, Muders M, Matz-Soja M, Krawczak M, Gasparoni G, Hartmann H, Dahl A, Schafmayer C, Walter J, Hampe J.
Nat Commun. 2018;9(1):4150.

 

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.

Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders MH, Meinhardt M, Baretton GB, Dummer R, Flaherty K, Pichler BJ, Kulms D, Westphal D, Meier F.
Clin Cancer Res. 2016;22(23):5818-5828.

 

Neuropilin-2 Regulates Endosome Maturation and EGFR Trafficking to Support Cancer Cell Pathobiology.

Dutta S, Roy S, Polavaram NS, Stanton MJ, Zhang H, Bhola T, Hönscheid P, Donohue TM Jr, Band H, Batra SK, Muders MH, Datta K.
Cancer Res. 2016;76(2):418-28.

 

The histone demethylase UTX regulates stem cell migration and hematopoiesis.

Thieme S, Gyárfás T, Richter C, Özhan G, Fu J, Alexopoulou D, Muders MH, Michalk I, Jakob C, Dahl A, Klink B, Bandola J, Bachmann M, Schröck E, Buchholz F, Stewart AF, Weidinger G, Anastassiadis K, Brenner S.
Blood. 2013;121(13):2462-73.

 

Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta.

Kwon J, Stephan S, Mukhopadhyay A, Muders MH, Dutta SK, Lau JS, Mukhopadhyay D.
Cancer Res. 2009;69(4):1350-7.

 

Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer.

Zhang H, Muders MH, Li J, Rinaldo F, Tindall DJ, Datta K.
Cancer Res. 2008;68(21):8770-8.